These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3086893)

  • 21. Inhibition of aldose reductase by 3',4'-dihydroxyflavones.
    Okuda J; Miwa I; Inagaki K; Horie T; Nakayama M
    Chem Pharm Bull (Tokyo); 1984 Feb; 32(2):767-72. PubMed ID: 6428761
    [No Abstract]   [Full Text] [Related]  

  • 22. [Preventional and therapeutic effects of aldose reductase inhibitor FR74366 on rat galactose cataract].
    Tsuji T; Matsumoto Y; Mori K; Ikebe H; Terubayashi H; Akagi Y; Tanimoto T
    Nippon Ganka Gakkai Zasshi; 1990 Feb; 94(2):120-7. PubMed ID: 2114732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Aldose reductase inhibitors].
    Dostert P; Strolin Benedetti M
    J Pharmacol; 1986; 17(4):483-96. PubMed ID: 3104688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altering the course of cataracts in diabetic rats.
    Fukushi S; Merola LO; Kinoshita JH
    Invest Ophthalmol Vis Sci; 1980 Mar; 19(3):313-5. PubMed ID: 6766909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity correlation of flavonoids for inhibition of bovine lens aldose reductase.
    Iinuma M; Tanaka T; Mizuno M; Katsuzaki T; Ogawa H
    Chem Pharm Bull (Tokyo); 1989 Jul; 37(7):1813-5. PubMed ID: 2509087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacophor requirements of the aldose reductase inhibitor site.
    Kador PF; Sharpless NE
    Mol Pharmacol; 1983 Nov; 24(3):521-31. PubMed ID: 6415401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.
    Datiles M; Fukui H; Kuwabara T; Kinoshita JH
    Invest Ophthalmol Vis Sci; 1982 Feb; 22(2):174-9. PubMed ID: 6799419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in the susceptibility of various aldose reductases to inhibition. II.
    Kador PF; Kinoshita JH; Tung WH; Chylack LT
    Invest Ophthalmol Vis Sci; 1980 Aug; 19(8):980-2. PubMed ID: 6773903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of lens-aldose reductase activity by brazilin and haematoxylin.
    Moon CK; Yun YP; Lee JH; Wagner H; Shin YS
    Planta Med; 1985 Feb; (1):66-7. PubMed ID: 3925476
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of a new aldose reductase inhibitor on various tissues in vitro.
    Terashima H; Hama K; Yamamoto R; Tsuboshima M; Kikkawa R; Hatanaka I; Shigeta Y
    J Pharmacol Exp Ther; 1984 Apr; 229(1):226-30. PubMed ID: 6423811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-activity studies of aldose reductase inhibitors containing the 4-oxo-4h-chromen ring system.
    Kador PF; Sharpless NE
    Biophys Chem; 1978 Mar; 8(1):81-5. PubMed ID: 417745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidiabetic and aldose reductase activities of biflavanones of Garcinia kola.
    Iwu MM; Igboko OA; Okunji CO; Tempesta MS
    J Pharm Pharmacol; 1990 Apr; 42(4):290-2. PubMed ID: 1974302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What is the nature of the charge transfer interaction at the aldose reductase inhibitor site.
    Kador PF; Nakayama T; Sato S; Smar M; Miller DD
    Prog Clin Biol Res; 1989; 290():237-50. PubMed ID: 2498900
    [No Abstract]   [Full Text] [Related]  

  • 34. [Experimentally induced diabetic retinal microangiopathy and polyol pathway. II. Effect of aldose reductase inhibitors on microangiopathy].
    Kojima K; Matsubara H; Mizuno K; Harada T; Suzuki M; Hotta N; Kakuta H; Sakamoto N
    Nippon Ganka Gakkai Zasshi; 1985 Feb; 89(2):247-56. PubMed ID: 3923790
    [No Abstract]   [Full Text] [Related]  

  • 35. An artificial intelligence approach to the study of the structural moieties relevant to drug-receptor interactions in aldose reductase inhibitors.
    Klopman G; Buyukbingol E
    Mol Pharmacol; 1988 Dec; 34(6):852-62. PubMed ID: 3143909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. QSAR prediction of inhibition of aldose reductase for flavonoids.
    Mercader AG; Duchowicz PR; Fernández FM; Castro EA; Bennardi DO; Autino JC; Romanelli GP
    Bioorg Med Chem; 2008 Aug; 16(15):7470-6. PubMed ID: 18585047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A study of the limitations of ARI treatment of streptozotocin-induced diabetic cataracts].
    Kojima M; Sasaki K
    Nippon Ganka Gakkai Zasshi; 1986 Dec; 90(12):1669-73. PubMed ID: 2950739
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibition of aldose reductases from rat and bovine lenses by flavonoids.
    Okuda J; Miwa I; Inagaki K; Horie T; Nakayama M
    Biochem Pharmacol; 1982 Dec; 31(23):3807-22. PubMed ID: 6818971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of chronic complications of diabetes mellitus with aldose reductase inhibitors].
    Cattalini M; Lerario AC
    Rev Assoc Med Bras (1992); 1996; 42(2):109-14. PubMed ID: 9110460
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of aldose reductase from rat nervous tissue by metabolites of cyclandelate.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():31-3. PubMed ID: 6430320
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.